KRAS and pancreatic ductal adenocarcinoma: Understanding the mechanisms underlying Kirsten rat sarcoma (KRAS) mutation‐driven development and progression of pancreatic ductal adenocarcinoma (PDAC) may facilitate the discovery of novel strategies for KRAS‐mutant PDAC (KRASmut‐PDAC) treatment.